Ovarian aging leads to a decrease in the quantity and quality of oocytes. Aged oocytes have significantly reduced amounts of mitochondria, the energy factories of cells, leading to lower fertilization rates and poor embryonic development. Various techniques have tried to use heterologous or autologous sources of mitochondria to reestablish oocyte health by providing more energy. However, heterologous sources are no longer used owing to the known risk of heteroplasmy. Although autologous methods have recently been tested in humans, they have not shown a clear improvement in embryo quality. In this review, we describe the techniques that have been tested in recent years to provide a state of the art on oocyte rejuvenation through extra injection of mitochondria. (Fertil Steril Ò 2019;111:219-26. 
A dvanced maternal age is considered to be the major cause of infertility in developed countries. Women have delayed the age to desired motherhood, bringing along an associated decline in oocyte yield and euploid embryo rates (1, 2) . Embryonic aneuploidies are mostly related to impaired capability of old oocytes to organize microtubules during spindle assembly, one of the most energy-consuming steps of meiosis resumption (3) . In fact, increased probability of an error during the second meiotic division has been related to mitochondrial dysfunction (4, 5) . Therefore, insufficiency in cell energetics due to low mitochondrial adenosine triphosphate (ATP) synthesis could be considered a cause of chromosomal aberrations and could determine both oocyte and embryo quality (6) , because ATP levels have been correlated with improved in vitro fertilization (IVF) outcomes in human oocytes (7) .
Increasing age is associated with reduced mitochondrial endowment in granulosa cells (8) and more numerous deletions in ovarian mitochondrial DNA (9) . Moreover, mitochondrial DNA copy number in oocytes from patients with previous fertilization failure due to unknown causes is significantly lower than in patients with fertilization failure due to severe sperm factor (10) .
Due to the relevance of aging in infertility, methods to rejuvenate and improve oocyte quality have been developed by introducing new sources of energy (11) . Nonhuman animal studies show that impaired mitochon-drial function leads to reduced preimplantation development of bovine oocytes and that mitochondrial supplementation into those oocytes restores embryo developmental capability, producing healthy calves (12) . In humans (13) (14) (15) , as in multiple other animal species (4, 12, (16) (17) (18) , the addition of mitochondria or cytoplasm from donor oocytes to heterologous oocytes has been claimed to improve egg quality and IVF success.
Indeed, although not currently in use due to ethical burdens related to heteroplasmy (mixing of mitochondrial DNA from a donor oocyte with mitochondrial DNA from a recipient heterologous oocyte), 25 babies have been delivered by donor cytoplasm injection (13) (14) (15) . In these human studies, the presence of more than one source of mitochondrial DNA in the resulting egg was considered to be experimental and thus required further testing as mandated by the United States Food and Drug Administration (FDA). However, further testing was not pursued by the IVF clinics that published this approach, with the hope that new technologies could provide an autologous source of mitochondria. Furthermore, ethical concerns related to the babies' health and especially to the transmission of mitochondrial diseases from the donor led to the advice of the FDA to stop using these mitochondrial replacement techniques.
Creation of gametes from induced pluripotent cells by means of cell reprogramming could be an alternate source of healthy oocytes (and spermatozoa) and could change this practice. However, the well known epigenetic changes that occur in these cells limits use of this approach owing to safety concerns (19) . Pluripotent stem cells can be an interesting source of other cellular regeneration alternatives. Human pluripotent stem cells (20) display undifferentiated, round, and globular immature mitochondria, similar to those found in the human metaphase II (MII) oocyte (21) , perinuclearly localized and containing few cristae, characteristic of energy production by glycolysis instead of by oxidative phosphorylation.
Unlike induced pluripotent cells, ovarian or oogonial stem cells (OSCs) are unipotent and can differentiate only into the oocyte lineage, but they also contain the improved cell machinery and energetics of germline cells, so they could be an ideal source to repair aged cell content from old oocytes. Although there is controversy related to the existence of these cells (22) , several groups propose that OSCs can be collected, cultured, and developed into oocytes under certain conditions (23, 24) . Therefore, OSCs could be a perfect source for mitochondrial supplementation, because they represent an autologous source of mitochondria that can be obtained from the patient herself. This approach seems to solve challenges raised by the use of heterologous mitochondrial donor oocytes and the ethical burdens associated with heteroplasmy because there is only one source of mitochondrial DNA (OSCs and recipient oocytes from same patient).
In this review, we aim to provide an overview of state of the art techniques for mitochondrial supplementation when applied as a tool to increase oocyte developmental potential and oocyte rejuvenation. With this purpose, advantages and limitations of each mitochondrial source and procedure are highlighted in the quest for a suitable and successful source of young, healthy, autologous mitochondria to improve oocyte and embryo quality. All the methods described are used once the first meiotic division has occurred; the mitochondrial supplementation at this stage can not repair any aneuploidy that originated before.
TECHNICAL APPROACHES FOR OOCYTE REJUVENATION
Oocyte rejuvenation by mitochondrial supplementation has been achieved at varying success rates following approaches that include heterologous or autologous mitochondrial replacement. In this section, we review such approaches and discuss their goals and biases. A scheme of these techniques is shown in Figure 1 .
Heterologous Approach
Partial cytoplasm transfer. Partial cytoplasm transfer (or cytotransfer) implies transference of several components included as a portion of donor oocyte cytoplasm or cytoplasm to restore recipient oocyte competence and improve embryo quality. Unlike transfer of isolated mitochondria, this technique also involves transfer of other cytoplasmic organelles, metabolic intermediates, energy factors, proteins, and a diverse pool of RNAs present in the human oocyte (25) (26) (27) (28) (29) .
Two approaches were initially investigated with this purpose: fusion of donor oocyte cytoplast (membrane-enclosed cytoplasm fraction) with patient oocyte, or direct injection of a small amount of donor cytoplasm into a patient oocyte. Normal fertilization rates are significantly higher after direct cytoplasm injection (63%, five cases) compared with fusion (23%, three cases) (14) . Therefore, the fusion approach was abandoned and replaced by a more efficient and simple technique consisting of a modified intracytoplasmic sperm injection (ICSI) procedure, where both the sperm and 5%-10% of donor cytoplasm are simultaneously injected into a recipient oocyte. This methodology was used for the majority of reported cytoplasm transfers (14, 30) .
Several sources of donor cytoplasm have been tested for transference, including fresh and cryopreserved MII oocytes and tripronuclear zygotes. Depending on the developmental cell-cycle stage between donor and recipient cells, procedures were also described as synchronous transfer (when both cells were at the same stage, MII to MII) or asynchronic (interphase zygote cytoplasm into MII [13, 31] ), challenging the rationale behind the original idea (32, 33) .
Using synchronous cytotransfer, a total of 21 babies out of 78 IVF procedures have been born (13, 15, 34, 35) . Regarding asynchronous transfers, five offspring out of nine IVF procedures were achieved in patients who had repeated implantation failure (36) . Fresh donor oocytes have been the most used cytoplasm source. However, this strategy demands exquisite synchrony between donor and recipient oocyte retrievals. Thus, cryopreserved oocytes seem to be a good option to facilitate the entire process, as suggested by pregnancies (15, 34) and live births of healthy male and female babies in young patients with poor embryo quality (15) . However, the competence of such cryopreserved cytoplasm still needs to be quantified, because it did not improve clinical outcomes in patients with advanced maternal age (34) .
Concerns with mitochondrial heteroplasmy prompted a search for the presence of donor mitochondrial DNA in the recipients. This active search demonstrated that donor mitochondrial DNA lasts throughout development, with positive results in arrested embryos, amniocytes, placentas, fetal cord, and blood saliva smears of children (13, 37, 38) . As recently demonstrated by Chen et al. (38) , such tissue heteroplasmy did not negatively affect cytotransfer in children aged 13-18 years (38) . However, because available data are rather limited and the research did not continue, the benefit of cytotransfer remains unknown.
Total cytoplasm transfer. Total cytoplasm transfer refers to thorough replacement of a pathologic cytoplasm with a competent one with the use of nuclear transfer technology. This strategy, originally proposed to overcome maternal mitochondrial disease transmission by transferring the maternal spindle into a healthy recipient donor cytoplasm (the ''threeparent baby'' technique), may also provide a potential therapeutic option for women who suffer from age-related infer-tility by transferring the germinal vesicle (GV) nucleus or metaphase spindle from an older woman's oocyte into a donated cytoplasm from a young woman. Whereas both GV and spindle transfer techniques have been extensively explored in nonhuman domestic mammals (39) (40) (41) (42) (43) (44) (45) , the unique ''three-parent baby'' technique to avoid mitochondrial disease transmission (39) requires a thorough safety assessment and alternate genetic sources before clinical implementation in humans.
Technically, GV transfer is efficient in all studied species (mice, humans, and rabbit). Moreover, it has been reported that the invasive nuclear handling does not compromise fertilization or subsequent embryo development to the blastocyst stage. In this scenario, efficiency might be due to recipient cytoplast competence. Thus, using the human model or xeno-oocytes (human nuclear origin and immature GV cytoplasm from rabbit or mice [46] ), transferred GV can progress to the MII stage but follows cytoplasmic dominance for species-specific maturation dynamics and rates. In mice, the procedure is reported to be 12%-18% to term (42) . In humans, studies report that four out of seven human oocytes reconstructed from GV of old oocytes (women aged >38 y) with cytoplasm of young oocytes (women aged <31 y) display normal second meiotic chromosome complement (45) . Furthermore, in the limited number of observations of an aged GV transferred into a younger ooplasm, an appropriate chromosomal segregation was recorded, demonstrating that this kind of human GV-reconstituted oocyte is able to undergo maturation, fertilization, and embryo cleavage, maintaining normal ploidy (47) .
Ultrastructure studies of human GV oocytes show that some mitochondria adjacent to the GV are likely carried over into reconstructed oocytes during GV transfer (26) , thus creating mitochondrial DNA heteroplasmy. Therefore, besides the maturation process itself, which requires improvement, a challenge in most GV transfer techniques is to completely remove mitochondrial DNA from the patient when performing GV transfer. Similarly, spindle transfer is technically reliable in several nonhuman mammalian species. However, in mice, nearly 5.5% heteroplasmy is detected in pups from F1 and F2 after GV transfer (48) .
Similar to mitochondrial ''contamination'' due to GV transfer, pronuclear (PN) transfer also induces a high level of heteroplasmy in mice (48) . In humans, several ethical concerns rule out this strategy, because embryo generation and destruction are required for subsequent parental reconstruction on a healthy cytoplasm.
Alternatively, Wakayama and Yanagimachi (49) proposed and demonstrated the potential reproductive use of all four subproducts of meiosis in mice. The two polar bodies (PBs) have been used for reproductive endings and live-born pups (48, 49) . According to this methodology, Wang et al. (48) studied mitochondrial content in F1 and F2 generations derived from PB transfer and observed undetectable heteroplasmy levels, particularly for 1PB. In humans, the reproductive result of PB nuclear transfer has recently been demonstrated (50) . Likewise, PB and PN could be considered as potential techniques to improve oocyte quality impaired by factors such as aging (51, 52) .
Chromosome transplantation by means of spindle transfer as a nuclear transfer procedure was successfully developed and tested by Tachibana et al. (53) in rhesus monkey oocytes and requires only minor modifications for clinical application in humans (54, 55) , supposing the maximum cytoplasm replacement. Mature MII oocytes are considered an ideal source for spindle isolation and transfer compared with GVs, requiring previous activation, are preferable to zygotes, also used for PN transfer, because they overcome ethical burdens associated with discarding zygotes.
Briefly, spindle transfer consists of transference of the birefringent spindle, enclosed into a karyoplast, from a patient oocyte to the perivitelline space of a cytoplast (MII enucleated donor oocyte) containing healthy mitochondria. Both membranes from the karyoplast and cytoplast should be integrated before fertilization of the generated oocyte (56) . Required karyoplasm-cytoplasm membrane fusion can be assessed by means of two methods: electrofusion or with the use of an extract from Sendai virus.
The first live birth after spindle transfer was achieved in a 36-year-old woman with asymptomatic Leigh syndrome who carried the mitochondrial genome mutation 8993T>G in subunit 6 of the ATPase gene. In that report, a total of 29 oocytes were obtained from the patient after initiation of two stimulation protocols, nine of which were MII oocytes. Five of these oocytes (one vitrified and warmed and four fresh) underwent spindle transfer followed by ICSI, and a total of four blastocysts were obtained and screened for chromosomal aneuploidy by means of array comparative genome hybridization. Only one blastocyst was euploid and therefore transferred into the patient. With the use of this procedure, the authors achieved a carryover rate of <6% (39) .
Nevertheless, and despite the encouraging live birth, several controversies were raised after publication of this study, some related to ethical concerns (57-61) and others to weakness in technical aspects of the procedure (62) . In the report, membrane fusion was achieved with the use of a modified electrofusion procedure to avoid virus protein transmission (39)-a technique inducing oocyte activation and, as suggested by Tesarik et al. (62, 63) , a probable cause of the observed high aneuploidy rate (75%). A recent study (64) using similar methodology seems to overcome the increased aneuploidy rate to restore embryo developmental potential in mouse oocytes, because the resulting offspring showed health and behavioral status similar to control offspring. In fact, preclinical assessment of the technique in human oocytes showed that the quality of the recipient oocyte, rather than the fusion method, might be the key factor leading to the impairment of resulting embryos (65) . This study highlights the role of spindle transfer as a feasible tool for mitochondrial supplementation for impaired oocytes.
In conclusion, a heterologous approach to rejuvenate the oocyte is effective, suggesting that mitochondria or other unknown cytoplasmic factors are available in the donor metaphase cytoplasm and contribute to improved recipient oocyte competence. However, inherent heteroplasmy can not be ruled out, so the clinical impact must be viewed with skepticism as yet.
Autologous Approach
To solve concerns raised by the use of heterologous donor mitochondria, autologous germinal mitochondria are available from OSCs or egg precursor cells (EggPCs) from the same patient. The procedure of injecting EggPC mitochondria with a sperm during the ICSI procedure was commercialized in 2014 by the U.S. company Ovascience. This specific procedure, branded as Augment, was launched as a treatment to improve ''egg health'' (66) . These mitochondria were isolated from EggPCs present in ovarian cortical tissue and found through the use of antibodies specific to the human VASA analogue, a cell surface protein found on these cells (23) .
Briefly, cortical tissue is obtained by means of laparoscopic ovarian biopsy under general anesthesia and is frozen until the day of the ICSI procedure. After thawing, ovarian tissue is processed to obtain the DDX4-positive EggPC population from a single-cell suspension, which is pelleted by centrifugation to release mitochondria. During ICSI, 1-2 pL of mitochondrial suspension is injected along with the spermatozoon, without any additional microinjection.
Clinical experience with Augment. Canada, United Arab Emirates, and Turkey are a few selected countries where women have had access to the Augment treatment since 2014. On May 7, 2015, a press release announced the first birth of a healthy child resulting from this technique. In the same year, two reports from these sites claimed improved pregnancy rates in poor-prognosis patients undergoing IVF, thanks to the use of this novel technique.
Fakih et al. (67) published results from 59 patients (mean age 37.3 y) from the Fakih IVF clinic (United Arab Emirates) and 34 patients (mean age 36 y) from TCART Fertility Partners (Canada). This prospective cohort (Fakih Clinic) and descriptive analysis (TCART) used patient histories to compare pregnancy rates and found differences between the two clinics. For example, Fakih IVF allocated eggs for Augment or control but did not use a randomized design, which could be a bias because there was a significant difference in egg allocation (106 IVF-only vs. 171 Augment). However, TCART lacked control samples; all eggs received Augment treatment. The authors reported marked improvement in pregnancy rates over the historic IVF success rate for these patients (e.g., 11-fold and 18-fold increases in ongoing pregnancy rate in United Arab Emirates and Canada, respectively). Nevertheless, these results must be interpreted with caution, because the analysis has some limitations. For example, the results came from two different clinics and countries with different IVF conditions. In addition, there is no well-defined control group or prospective design, and embryologists were not blinded when selecting the embryo for transfer.
Oktay et al. (68) reported results from 16 patients (mean age 35.2 y) from Genart Ankara (Turkey) with at least two IVF failures due to bad oocyte/embryo quality. Ten out of 16 patients completed the Augment technique and had embryo transfer. However, this study is limited by its study population and protocol, because not all patients followed the same procedures. For example, four patients underwent preimplantation genetic testing for aneuploidy (two ongoing pregnancies) and six did not (0 ongoing pregnancies). In addition, the sample size was very small, and there was no prospective design. The study compared results with those obtained by the same patients in previous cycles and described an increase in fertilization rate (P¼ .036) and a tendency for better embryo quality on day 3 (P¼ .082), which the authors attributed to the fact that Augment can improve oocyte quality.
Due to the lack of well designed studies on the use of this technique, our group at IVI-RMA Valencia (Spain) performed a triple-blind, randomized, single-center, controlled experimental pilot study. A total of 59 patients were included, with a mean age of 36.3 years and 2.5 previous failed IVF cycles. Briefly, day-5 blastocyst formation rate was significantly higher in the control group, suggesting that this technique does not improve embryo development potential in this population. Moreover, no differences were observed in the euploid rate per MII or biopsied blastocyst, mitochondrial DNA content, or cumulative live birth rate per transferred embryo (69) . Interestingly, 46% of patients who underwent oocyte retrieval did not have embryos available for transfer even though they received the Augment technique. Interim analysis therefore stopped patient recruitment, considering the invasiveness and high cost of the technique with a lack of improvement in results.
Taking into consideration the limitations of the first published studies and the lack of improvement in the randomized study, we conclude that, as currently designed, autologous germline mitochondrial energy transfer is not a feasible treatment to improve embryo quality in IVF.
INNOVATIVE APPROACHES
From these unexpected results, several innovative approaches from different research groups are within the scope of interfering in the oocyte aging process. Search for better sources of mitochondria and organelle improvement by means of gene editing/engineering or culture media additives to combat the stress caused by aging are among the most challenging approaches.
Autologous sources of young mitochondria other than EggPCs have been proposed (70) . Ideally, new sources should be obtained by less invasive methods and preferably without involving the ovarian tissue to preserve intact ovaries for future stimulation with gonadotropins. Hematopoietic stem cells, stromal cell lines, and adipose-derived stem cells can be found among these theoretically suitable autologous sources (70) (71) (72) . Human pluripotent cells (20) contain improved cell machinery and energetics and therefore could be considered an ideal source to repair cell content from old oocytes. Nevertheless, current options of using adult stem cells are reduced and limited to rodent models (70) or to the hypothetic development of new technologies to produce synthetic mitochondria (73) free of disease and aging.
Mitochondrial replacement therapy with the use of CRISPR/Cas9 gene editing to restore mutated mitochondria of oocytes from women of advanced maternal age is another possibility that can be explored over the coming years. This technology has been proposed for patients with mitochondrial diseases (74, 75) . Although it raises uncertainty and ethical concerns, its application to oocytes to improve mitochondrial fitness remains an open possibility.
Finally, addition of molecules into the culture media of oocytes is another possibility currently being explored. Molecules such as nitric oxide (76) or antioxidant molecule cocktails (77) have been shown to improve embryo development in old female mice. Likewise, diet supplementation with antioxidant molecules such as coenzyme Q10 (CoQ10) has been explored, with increasing developmental potential of oocytes in aged nonhuman animal models (78) . Nevertheless, in humans no significant improvement in pregnancy or euploidy rates have been achieved so far (79) . Recent studies suggested a positive effect of oral CoQ10 administration on the antioxidant status of follicular fluid, which may potentially improve oocyte quality in women over 35 years of age, but its clinical relevance remains uncertain (80) .
CONCLUSION
Various strategies have been tested to increase the mitochondria content and thus improve the quality of oocytes. The first studies were conducted with a heterologous source of mitochondria, usually from young egg donors, but these techniques were abandoned due to the risk of mixing two sources of mitochondrial DNA. Therefore, alternate strategies looked for autologous sources of mitochondria after the discovery of putative EggPCs in the ovarian cortex.
In 2013, the Augment technique was proposed as a novel tool to improve embryo quality in humans (66) and was presented as a solution to solve the ethical objections associated with heteroplasmy without the hypothetic risk of mitochondrial disease inheritance. Although initial descriptive studies seemed promising, a recent prospective study (69) could not demonstrate a clear improvement in either pregnancy rates or embryo development. In fact, when mitochondrial supplementation was provided to aged oocytes (67) , an absence of significant efficacy was observed. Altogether, these findings could be partially explained by the time of supplementation, because mitochondria are supplied to the MII oocyte stage whereas the highest risk of age-related misalignments is associated with the first meiotic division. Alternate and innovative approaches are being proposed but remain in very early stages-thus, the search for an effective solution to oocyte rejuvenation continues.
